C2N Diagnostics - Articles and news items

FDA orphan drug designation for C2N-8E12 for the treatment of progressive supranuclear palsy

Industry news / 20 July 2015 / Victoria White

The US FDA has granted C2N-8E12 (ABBV-8E12) an orphan drug designation for the treatment of progressive supranuclear palsy (PSP)…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+